RYE, N.Y., July 28 /PRNewswire/ — Curemark, LLC
(www.curemark.com), a drug
research and development company focused on the treatment of
neurological diseases, announced that Saint Peter’s University
Hospital in New Brunswick, New
Jersey, is participating in the company’s Phase III clinical
trials for CM-AT, Curemark’s autism
Saint Peter’s is affiliated with the Drexel
University College of Medicine in Philadelphia. Drexel University
College of Medicine began enrolling patients in the CM-AT autism
study earlier this year. Curemark’s clinical trial program
for CM-AT now encompasses a total of 13 sites nationwide.
CM-AT, which has received Fast Track status from the FDA, is
based on Curemark’s research that showed enzyme deficiencies in
autistic children, resulting in an inability to digest protein.
The inability to digest protein affects the availability of
amino acids, the building blocks of chemicals essential for brain
function. If approved, CM-AT will be one of the first
therapies to address the underlying physiology of autism.